Log in or register to see all Alerts
New HTA Decisions in England
April 2019
Drug name
CIMZIA® (Certolizumab pegol)
Company
UCB
Decision date
17/04/2019
Therapeutic area
Skin conditions
Therapeutic sub area
Psoriasis
Decision
Recommended with restrictions
Indication
Certolizumab pegol is recommended as an option for treating plaque psoriasis in adults
Decision Detail
Certolizumab pegol is only recommended under the following circumstances - (1) the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and (2) the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and (3) the lowest maintenance dosage of certolizumab pegol is used (200 mg every 2 weeks) after the loading dosage and (4) the company provides the drug according to the commercial arrangement.
Summary
Clinical trial results show that certolizumab pegol improves severe plaque psoriasis more than either placebo or etanercept. When compared indirectly, it appears to be as effective as other biological treatments for the condition, and also appears to be more effective than non-biological treatments. Certolizumab pegol treatment is considered a cost-effective use of NHS resources only when its lowest licensed maintenance dosage is used and in patients that have not responded to systemic non-biological treatments, or if these are contraindicated or not tolerated.